152 related articles for article (PubMed ID: 20466412)
1. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women.
Kim JH; Shin MH; Kweon SS; Park MH; Yoon JH; Lee JS; Choi C; Fackler MJ; Sukumar S
Gynecol Oncol; 2010 Aug; 118(2):176-81. PubMed ID: 20466412
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.
Fackler MJ; McVeigh M; Evron E; Garrett E; Mehrotra J; Polyak K; Sukumar S; Argani P
Int J Cancer; 2003 Dec; 107(6):970-5. PubMed ID: 14601057
[TBL] [Abstract][Full Text] [Related]
3. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
Moelans CB; Verschuur-Maes AH; van Diest PJ
J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
[TBL] [Abstract][Full Text] [Related]
4. Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis.
Lee JS; Fackler MJ; Teo WW; Lee JH; Choi C; Park MH; Yoon JH; Zhang Z; Argani P; Sukumar S
Cancer Biol Ther; 2008 Sep; 7(9):1398-406. PubMed ID: 18769130
[TBL] [Abstract][Full Text] [Related]
5. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARĪ²2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylated genes as biomarkers of cancer in women with pathologic nipple discharge.
Fackler MJ; Rivers A; Teo WW; Mangat A; Taylor E; Zhang Z; Goodman S; Argani P; Nayar R; Susnik B; Sukumar S; Khan SA
Clin Cancer Res; 2009 Jun; 15(11):3802-11. PubMed ID: 19470737
[TBL] [Abstract][Full Text] [Related]
7. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
8. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens.
Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Kweon SS; Fackler MJ; Sukumar S
Virchows Arch; 2010 Jul; 457(1):35-42. PubMed ID: 20496080
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
11. Promoter CpG island hypermethylation during breast cancer progression.
Park SY; Kwon HJ; Lee HE; Ryu HS; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
Virchows Arch; 2011 Jan; 458(1):73-84. PubMed ID: 21120523
[TBL] [Abstract][Full Text] [Related]
12. Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients.
Shukla S; Mirza S; Sharma G; Parshad R; Gupta SD; Ralhan R
Epigenetics; 2006; 1(2):88-93. PubMed ID: 17998817
[TBL] [Abstract][Full Text] [Related]
13. Quantitative assessment of DNA methylation for the detection of cervical and endometrial adenocarcinomas in liquid-based cytology specimens.
Kim GE; Kweon SS; Lee JS; Lee JH; Nam JH; Choi C
Anal Quant Cytopathol Histpathol; 2012 Aug; 34(4):195-203. PubMed ID: 23016466
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer.
Verschuur-Maes AH; de Bruin PC; van Diest PJ
Breast Cancer Res Treat; 2012 Dec; 136(3):705-15. PubMed ID: 23104224
[TBL] [Abstract][Full Text] [Related]
16. Detection of Slit2 promoter hypermethylation in tissue and serum samples from breast cancer patients.
Kim GE; Lee KH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
Virchows Arch; 2011 Oct; 459(4):383-90. PubMed ID: 21894562
[TBL] [Abstract][Full Text] [Related]
17. Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes.
Van der Auwera I; Bovie C; Svensson C; Limame R; Trinh XB; van Dam P; Van Laere SJ; Van Marck E; Vermeulen PB; Dirix LY
Cancer Biol Ther; 2009 Dec; 8(23):2252-9. PubMed ID: 19829046
[TBL] [Abstract][Full Text] [Related]
18. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
[TBL] [Abstract][Full Text] [Related]
20. [Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Xu GW; Deng GR
Ai Zheng; 2007 Jan; 26(1):44-7. PubMed ID: 17222366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]